UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to…
16,250€
9,06%
Echtzeit-Aktienkurs UroGen Pharma Ltd
Bid:
Ask:
Nachrichten zur UroGen Pharma Ltd Aktie
UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen…
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm
NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
UroGen Pharma: Lessons Learned And Future Outlook
…
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. (URGN) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…
URGN Investors with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against UroGen Pharma Ltd.
Robbins LLP is Investigating Allegations that UroGen Pharma Ltd. (URGN) Failed to Conduct a Proper Trial for its Lead Drug…
Kirby McInerney LLP Reminds UroGen Pharma Ltd. (URGN) Investors of Class Action Filing and Encourages Investors to Contact the Firm
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors who…
UroGen Pharma Ltd. Investors: Please contact the Portnoy Law Firm to recover your losses. July 28, 2025 Deadline to file Lead Plaintiff Motion.
Investors can contact the law firm at no cost to learn more about recovering their losses…
UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But Its Not Over, Either
…
Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?
Urogen Pharma (URGN) saw its shares surge in the last session with trading volume being higher than average. The latest…
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.11% and 6.08%, respectively, for the quarter ended December 2024. Do…
UroGen Pharma: Choice Based On Near-Term High-Value PDUFA
…
UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript
…
UroGen Pharma: There Is Some Potential Here
…
UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript
…
UroGen Pharma stock maintains target post-offering By Investing.com
UroGen Pharma stock maintains target post-offering…
UroGen Pharma commences public offering of ordinary shares
…
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to…
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…
UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript
…
Urogen Pharma executive sells shares worth over $168k By Investing.com
Urogen Pharma executive sells shares worth over $168k…
UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript
…
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.46% and 5.52%, respectively, for the quarter ended December 2023. Do…